In a nonsurgical population-based cohort that included 25,617 patients, Faillie et al. reported that patients receiving GLP-1RAs had an increased risk of intestinal obstruction compared to SGLT-2 inhibitors (HR 3.48; 95% CI 1.79, 6.79) (Faillie et al. 2022). This evidence concerns the gene SLC5A2 and intestinal obstruction.